GSK stock falls more at London open following RSV vaccination news
By Steve Goldstein
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.
GSK's London-listed shares (UK:GSK) were trading at GBP14.91 in early action Thursday, a decline of 7%, and worse than the GBP15.44 implied by the U.S. close.
Put a different way, the ADRs (GSK) will be around $37.66 when the U.S. market opens up again, based on the local trading.
GSK recently launched the Arexy vaccine to target RSV.
The Advisory Committee on Immunization Practices is now recommending RSV vaccination for all adults above 74 years in age, versus 60 years previously. They only recommended vaccination for those over 60 if at increased risk of RSV.
Analysts at JPMorgan also highlighted that Moderna (MRNA) received the same recommendation as GSK despite weaker data.
"We believe consensus Arexvy forecasts may now be lowered to reflect a smaller eligible U.S. patient population, confirmed Moderna competition, and more risk around GSK's two-year revaccination interval," they said.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-27-24 0358ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks